Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anqi Lin

Showing results (111-120 of 200) with videos related to

Pageof 20
Sort By:
Cancer Biomarkers : Section a of Disease Markers|December 3, 2023
Correlation between IL3 signaling pathway-related genes and immune checkpoint inhibitor efficacy in patients with renal cell carcinomaShuang Hou, Tianqi Gu, Ying Shi, et al.
Analytical Chemistry|June 27, 2022
A Dopamine-Enabled Universal Assay for Catalase and Catalase-Like NanozymesAnqi Lin, Quanyi Liu, Yihong Zhang, et al.
Cancer Gene Therapy|July 6, 2022
Application of ATAC-seq in tumor-specific T cell exhaustionChufeng Chen, Jiaying Liu, Yidong Chen, et al.
Cancer Letters|June 5, 2026
Nanomedicine Orchestrated Metabolic Reprogramming of Immune Cells in Antitumor ImmunityAnqi Lin, Yuhong Chen, Jiwei Liu, et al.
Communications Medicine|February 20, 2026
Integrating digital solutions improves mental health management in cancer careAnqi Lin, Yuquan Zhang, Aimin Jiang, et al.
Molecular Cancer|February 16, 2023
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatmentZhifei Gao, Yifeng Bai, Anqi Lin, et al.
Molecular Horticulture|September 13, 2024
Loss-of-function mutation in anthocyanidin reductase activates the anthocyanin synthesis pathway in strawberryPengbo Xu, Maobai Li, Chao Ma, et al.
Eclinicalmedicine|July 15, 2024
Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBaseJunyi Shen, Rong Hu, Anqi Lin, et al.
Nano Letters|December 30, 2021
Self-Cascade Uricase/Catalase Mimics Alleviate Acute GoutAnqi Lin, Ziying Sun, Xingquan Xu, et al.
Cancer Gene Therapy|August 8, 2020
EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinomaWeimei Huang, Anqi Lin, Peng Luo, et al.
Pageof 20

Showing results (111-120 of 200) with videos related to

Sort By:
Pageof 20
Cancer Biomarkers : Section a of Disease Markers|December 3, 2023
Correlation between IL3 signaling pathway-related genes and immune checkpoint inhibitor efficacy in patients with renal cell carcinomaShuang Hou, Tianqi Gu, Ying Shi, et al.
Analytical Chemistry|June 27, 2022
A Dopamine-Enabled Universal Assay for Catalase and Catalase-Like NanozymesAnqi Lin, Quanyi Liu, Yihong Zhang, et al.
Cancer Gene Therapy|July 6, 2022
Application of ATAC-seq in tumor-specific T cell exhaustionChufeng Chen, Jiaying Liu, Yidong Chen, et al.
Cancer Letters|June 5, 2026
Nanomedicine Orchestrated Metabolic Reprogramming of Immune Cells in Antitumor ImmunityAnqi Lin, Yuhong Chen, Jiwei Liu, et al.
Communications Medicine|February 20, 2026
Integrating digital solutions improves mental health management in cancer careAnqi Lin, Yuquan Zhang, Aimin Jiang, et al.
Molecular Cancer|February 16, 2023
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatmentZhifei Gao, Yifeng Bai, Anqi Lin, et al.
Molecular Horticulture|September 13, 2024
Loss-of-function mutation in anthocyanidin reductase activates the anthocyanin synthesis pathway in strawberryPengbo Xu, Maobai Li, Chao Ma, et al.
Eclinicalmedicine|July 15, 2024
Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBaseJunyi Shen, Rong Hu, Anqi Lin, et al.
Nano Letters|December 30, 2021
Self-Cascade Uricase/Catalase Mimics Alleviate Acute GoutAnqi Lin, Ziying Sun, Xingquan Xu, et al.
Cancer Gene Therapy|August 8, 2020
EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinomaWeimei Huang, Anqi Lin, Peng Luo, et al.
Pageof 20